Dr Jonathan Harry Erlich

 Dr Erlich work has focused on how cell signaling via the coagulation pathway contributes to inflammation in a variety of different scenarios. The work has largely examined the role of the protease activated coagulation cascade and its signaling via protease activated receptors in cardiac and renal ischaemia reperfusion injury, glomerulonephritis, and models of chronic renal scaring.

Current work has largely focused on renal ischaemia reperfusion injury (IRI) with recent work focusing on downstream intra cellular signaling pathways following PAR-1 signaling. The studies aim to define potential therapeutic targets that may limit and or potentially treat the problem of renal damage that occurs following renal IRI. This scenario is relevant to a wide range of clinical situations including aortic surgery and renal transplantation where renal IRI can be predicted. Currently employing mouse models we are investigating the mechanism by which inhibition of the PAR-1 receptor provides a degree of protecting against renal injury following IRI. Understanding the pathways involved provides an opportunity to develop interventions that may provide additive benefits. We are working to take out finding from mouse models of renal IRI to rat models of renal transplantation.